INTRODUCTION
============

Asthma and obesity are very prevalent diseases and are considered public health problems. Evidence from cross-sectional studies suggests that obese individuals are at increased risk of asthma and that obese individuals with asthma have more severe asthma, experience a greater number of hospitalizations, and make a greater number of emergency room visits.[@B1] ^,^ [@B2] However, the causal association of obesity with asthma prevalence and severity remains an object of study.

Studies aimed at clarifying the relationship between obesity and asthma have suggested that obesity has effects on respiratory mechanics, alters immune response, and has metabolic implications.[@B1] ^,^ [@B3] ^-^ [@B5] There is evidence that obesity increases the inflammatory process in the lungs of subjects with asthma. Pro-inflammatory mediators are directly correlated with abdominal visceral fat and can lead to increased bronchial hyperresponsiveness and bronchospasm.[@B6] ^,^ [@B7] Cross-sectional studies have also suggested that obese individuals with asthma have airway inflammation that is more neutrophilic than eosinophilic.[@B7] ^,^ [@B8]

Studies evaluating the relationship between obesity and asthma control have reported controversial findings.[@B9] ^,^ [@B10] In addition, there have been few studies evaluating the effects of obesity on the immunopathology of asthma. Therefore, the objective of the present study was to evaluate the relationship between obesity and asthma, regarding peripheral eosinophilia and neutrophilia, atopy, asthma severity, asthma control, and late-onset asthma.

METHODS
=======

*Study design*
--------------

This was a cross-sectional study evaluating subjects with mild-to-moderate or severe asthma. A total of 925 subjects treated by the Brazilian Unified Health Care System in the city of Salvador, Brazil, participated in the study. Participants were selected between January 2013 and July 2015 and were evaluated at the Federal University of Bahia Center of Excellence in Asthma, located in that same city. This study is part of a more comprehensive project, called "*Fatores de risco, biomarcadores e endofenótipos da asma grave*" (Risk factors and biomarkers for and endophenotypes of severe asthma) that was approved by the Brazilian National Research Ethics Committee (Ruling/Resolution no. 450/2010) and the Research Ethics Committee of the Federal University of Bahia Climério de Oliveira Maternity Hospital (Additional Resolution no. 095/2012).

*Study population*
------------------

Posters were placed in areas heavily used by pedestrians and in public transport vehicles, in order to recruit subjects with mild-to-moderate asthma throughout the city of Salvador. In addition, the research team advertised the study among patients and physicians at the primary care clinics affiliated with the public health care system in the city of Salvador, and interviews were conducted in the waiting rooms of those clinics. Subjects with severe asthma were selected from the cohort of subjects enrolled in the *Programa para o Controle da Asma na Bahia* (ProAR, Bahia State Program for the Control of Asthma), which is a major referral program providing specialized care in the treatment of severe asthma in the city of Salvador.[@B11]

The inclusion criteria were having physician-diagnosed asthma and being ≥ 18 years of age. All participants gave written informed consent. The exclusion criteria were being pregnant, having any disease severe enough to make it difficult to assess asthma symptoms or any other disease that causes dyspnea.

The subjects with mild-to-moderate asthma recruited from the community and primary care clinics were referred to a specialist at the *Núcleo de Excelência em Asma*-ProAR (NEA, Center of Excellence in Asthma-ProAR) at the Federal University of Bahia for confirmation of the diagnosis of asthma. For the subjects with severe asthma recruited from the cohort of subjects enrolled in the ProAR, the diagnosis of asthma was validated by two specialists at the NEA-ProAR. The specialists evaluated the subjects and reviewed their medical charts in order to confirm the diagnosis of asthma. The criteria for diagnosing asthma were typical symptoms, symptomatic improvement with a bronchodilator or an inhaled corticosteroid, and a 12% and 200 mL increase in FEV~1~ after bronchodilator use.

The subjects were classified as having mild-to-moderate asthma in accordance with the 2006 Global Initiative for Asthma guidelines[@B12] in order to use similar criteria to those used among the subjects with severe asthma, whose asthma severity was evaluated in accordance with the 2002 Global Initiative for Asthma guidelines,[@B13] which were in effect at the time the ProAR was established, and who fit the category of having untreated severe asthma as per the classification proposed to the World Health Organization in 2010.[@B14]

*Study procedures*
------------------

All subjects underwent blood collection, spirometry,[@B15] ^,^ [@B16] immediate skin-prick testing,[@B17] clinical evaluation by a specialist, and collection of fasting anthropometric measurements.

All subjects also completed the following questionnaires: the six-item Asthma Control Questionnaire[@B18]; the Asthma Quality of Life Questionnaire[@B19]; the Symptom Questionnaire for Gastroesophageal Reflux Disease[@B20]; and the Beck Depression Inventory.[@B21]

*Definitions*
-------------

Subjects with difficult-to-control asthma are those whose lack of asthma control is due to factors such as low adherence to medication, poor inhaler technique, environmental exposure, psychosocial problems, or comorbidities.[@B14]

Uncontrolled asthma was defined as a score ≥ 1.5 on the six-item Asthma Control Questionnaire.[@B18]

A high dose of inhaled corticosteroid was defined as use of more than 800 µg of budesonide daily.[@B22]

The criteria for the presence of airway obstruction were an FEV~1~ \< 80% of predicted and an FEV~1~/FVC ratio below the lower limit of normal.[@B23] This limit is adjusted for age, being obtained on the basis of the fifth percentile of healthy nonsmokers.

The criterion for the presence of atopy was a positive, immediate skin-prick test result. A test result was considered positive if the wheal to any allergen tested was ≥ 3 mm. The antigens tested were *Dermatophagoides pteronyssinus*, *Aspergillus flavus, Dermatophagoides farinae, Aspergillus fumigatus, Blomia tropicalis, Aspergillus niger*, cat dander, *Alternaria alternata*, dog dander, *Blatella germanica*, *Cladosporium herbarum*, *Periplaneta americana*, *Paspalum notatum*, and *Cynodon dactylon*.[@B17]

Late-onset asthma was defined as asthma diagnosed at age 18 years or older.[@B24] Eosinophilic asthma was defined as a peripheral blood eosinophil count greater than 260 cells/μL. Zhang et al.,[@B25] demonstrated that this cut-off point of peripheral blood eosinophil count has good ability to detect induced sputum eosinophilia.

The diagnostic criterion for comorbidities (hypertension, dyslipidemia, and/or diabetes) was a positive report of use of specific medications for each of those diseases.

Body weight was measured with a digital scale (Tanita, Arlington Heights, IL, USA), and height was measured with a wall-mounted wooden stadiometer graduated in cm from 40 to 220. Body mass index was calculated as body weight in kilograms divided by height in meters squared.[@B26] Obesity was defined on the basis of BMI (kg/m^2^) in accordance with the World Health Organization criteria-underweight: BMI \< 18.5; normal weight: 18.5 ≤ BMI ≤ 24.9; overweight: 25 ≤ BMI ≤ 29.9; and obesity: BMI ≥ 30.[@B26] Abdominal obesity was classified using abdominal circumference (AC), which was measured at the midpoint between the lowest rib and the iliac crest. Abdominal obesity was defined as an AC ≥ 80 cm in women and ≥ 90 cm in men.[@B27]

*Statistical analysis*
----------------------

We used the Statistical Package for the Social Sciences for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA). Associations were analyzed by BMI group and by abdominal obesity group. The chi-square test was used to detect associations between dichotomous variables, and the nonparametric Kruskal-Wallis test was used to compare three or more independent groups on continuous or ordinal variables. The Mann-Whitney test was used to compare two groups on continuous and ordinal variables with non-normal distribution. Continuous and ordinal variables are presented as mean and standard deviation and as median and interquartile range, respectively. Categorical variables are presented as absolute numbers and percentages.

RESULTS
=======

We included 925 subjects with asthma, and, of those, 299 were obese according to their BMI. [Table 1](#t1){ref-type="table"} presents the characteristics of participants by BMI group. As can be seen in this table, BMI was associated with gender, age, level of education, comorbidities, atopy, dose of inhaled corticosteroid, eosinophilic phenotype, and peripheral blood neutrophils (p \< 0.05).

Table 1Sociodemographic, clinical, and laboratory characteristics of the subjects included in the study, by body mass index group.^a^VariableBMI groupp\*UnderweightNormal weightOverweightObese(n = 20)(n = 286)(n = 319)(n = 299)Female gender17 (85)203 (71)245 (77)266 (89)\< 0.01Age, years34 ± 1940 ± 1647 ± 1447 ± 13\< 0.01Low level of education^b^3 (15)26 (9)47 (15)54 (18)0.02Late-onset asthma (≥ 18 years)4 (20)90 (31)120 (38)92 (31)0.14Comorbidities^c^2 (10)61 (21)130 (41)171 (57)\< 0.01Diagnosis of rhinitis18 (90)258 (91)300 (94)277 (93)0.42Positive skin-prick test result10 (50)191 (67)199 (62)163 (55)0.03Diagnosis of GERD8 (40)101 (35)141 (44)149 (66)0.38Severe depression^d^0 (0)10 (4)21 (7)26 (9)\< 0.01High dose of asthma medication^e^4 (20)102 (36)158 (50)173 (58)\< 0.01Total serum IgE, IU/mL237 (39-642)291 (115-542)261 (100-451)269 (105-530)0.64Eosinophils ≥ 260 cells/µL15 (75)141 (49)141 (44)134 (45)0.02Eosinophils, cells/µL433 (251-579)258 (137-401)232 (130-378)240 (139-383)0.01Neutrophils, cells/µL2,641 (1,922-4,938)3,399 (2,470-4,338)3,431 (2,394-4,533)3,711 (2,765-4,942)0.01[^1]

[Table 2](#t2){ref-type="table"} also presents data on participants by BMI group. Although BMI was associated with various pulmonary function parameters (p \< 0.05), there was no significant difference in the frequency of airway obstruction among the groups. BMI was associated with asthma symptoms, asthma-related quality of life, asthma exacerbations, and difficult-to-treat asthma (p \< 0.05).

Table 2Spirometric values and asthma severity parameters in the subjects included in the study, by body mass index group.^a^VariableBMI groupp\*UnderweightNormal weightOverweightObese(n = 20)(n = 286)(n = 319)(n = 299)Post-BD FVC, % of predicted82 (70-93)87 (79-95)86 (78-95)83 (75-92)\< 0.01Post-BD FEV~1~, % of predicted75 (62-95)82 (70-92)79 (67-90)75 (63-88)\< 0.01Post-BD FEF~25-75%~, % of predicted70 (46-90)73 (44-98)67 (35-94)62 (36-91)0.02Post-BD FEV~1~/FVC, % of predicted0.9 (0.7-0.9)0.8 (0.7-0.9)0.8 (0.6-0.8)0.8 (0.7-0.8)\< 0.01Airway obstruction^b^3 (15)35 (12)53(17)34 (11)0.26ACQ-6 score ≥ 1.54 (20)63 (22)75 (24)97 (32)0.02AQLQ score5.0 (3.7-5.9)5 (4-6)4.8 (3.7-5.8)4.5 (3.3-5.4)\< 0.01Oral corticosteroid use for asthma in the past year9 (45)100 (35)126 (40)151 (51)\< 0.01Severe difficult-to-treat asthma6 (30)97 (34)147 (46)179 (60)0.03[^2]

[Tables 3](#t3){ref-type="table"} and 4 present data on participants by abdominal obesity group. The groups differed in gender, age, level of education, late-onset asthma, comorbidities, atopy, dose of inhaled corticosteroid, eosinophilic phenotype, pulmonary function, asthma symptoms, asthma-related quality of life, and frequency of exacerbations (p \< 0.05).

Table 3Sociodemographic, clinical, and laboratory characteristics of the subjects included in the study, by abdominal obesity group.^a^VariableWithout abdominal obesityWith abdominal obesityp\*(n = 258)(n = 667)Female gender167 (65)564 (85)\< 0.01Age, years36 ± 1548 ± 14\< 0.01Low level of education^b^16 (6)114 (17)\< 0.01Late-onset asthma (≥ 18 years)67 (26)239 (36)\< 0.01Comorbidities^c^37 (14)327 (49)\< 0.01Diagnosis of rhinitis234 (91)620 (93)0.13Positive skin-prick test result174 (67)389 (58)0.01Diagnosis of GERD96 (37)303 (45)0.31Severe depression^d^4 (2)53 (8)\< 0.01High dose of asthma medication^e^75 (29)362 (54)\< 0.01Total serum IgE, IU/mL300 (114-566)262 (103-498)0.20Eosinophils ≥ 260 cells/µL138 (54)294 (45)0.01Eosinophils, cells/µL282 (143-464)236 (132-379)0.05Neutrophils, cells/µL3,326 (2,404-4,387)3,581 (2,529-4,663)0.09[^3]

Table 4Spirometric values and asthma severity parameters in the subjects included in the study, by abdominal obesity group.^a^VariableWithout abdominal obesityWith abdominal obesityp\*(n = 258)(n = 667)Post-BD FVC, % of predicted87 (80-95)85 (76-93)\< 0.01Post-BD FEV~1~, % of predicted84 (72-94)77 (64-89)\< 0.01Post-BD FEF~25-75%~, % of predicted78 (54-101)62 (35-91)\< 0.01Post-BD FEV~1~/FVC, % of predicted0.8 (0.7-0.9)0.8 (0.6-0.8)\< 0.01Airway obstruction^b^29 (11)96 (14)0.11ACQ-6 score ≥ 1.547 (18)192 (29)\< 0.01AQLQ score5.1 (4.2-6.0)4.6 (3.4-5.6)\< 0.01Oral corticosteroid use for asthma in the past year90 (35)296 (44)\< 0.01Severe difficult-to-treat asthma77 (29)352 (53)0.63[^4]

DISCUSSION
==========

Our findings indicated that obese subjects with asthma had a higher number of neutrophils and a lower number of eosinophils in peripheral blood compared with nonobese subjects with asthma. These observations suggest that asthma in obese individuals more commonly has a noneosinophilic immunopathological mechanism. This helps understand why obese subjects have more severe asthma, given that eosinophilic airway inflammation has better response to inhaled corticosteroid therapy.[@B7] ^,^ [@B8] ^,^ [@B10] ^,^ [@B28]

In our study, we analyzed immediate skin-prick test results because a positive result on this test is a marker of atopy; however, obesity was associated with negative skin-prick test results. Similar findings have been observed previously, with obesity defined either by BMI or AC; however, the mechanisms involving this association remain unknown.[@B29] ^-^ [@B31] Interestingly, we found no association between obesity and total peripheral blood IgE, which is also a marker of atopy. Further studies are needed to investigate whether obese individuals with asthma have lower levels of systemic Th2 immune activity or whether the association between asthma and negative skin-prick test results is due to specificities related to excess of subcutaneous adipose tissue.

Our findings also indicated an association between obesity and severe difficult-to-treat asthma. The obese individuals in our sample also had higher scores on the symptom questionnaire, poorer quality of life, and more frequent asthma exacerbations requiring oral corticosteroids than did the nonobese individuals. Although other authors have also observed these associations,[@B8] ^,^ [@B32] the present study contributes to the medical literature because it included a large sample of individuals with a broad spectrum of asthma severity, recruited from a referral center and the community. In addition, the subjects in the present study were followed by specialists and were provided free-of-charge treatment to control their asthma symptoms, which was not ensured in previous studies.

The obese individuals with asthma in the present study, when considering either BMI or AC, used higher doses of inhaled corticosteroids to control their asthma. This increased dependence on inhaled corticosteroids might be related to the lower frequency of noneosinophilic asthma in our sample of obese individuals, given that individuals with noneosinophilic asthma tend to have poorer response to corticosteroid therapy and, therefore, require higher doses of medication to control inflammation.[@B10] ^,^ [@B33]

Previous studies have demonstrated a relationship between age at asthma onset and the severity of respiratory symptoms in obese individuals.[@B30] ^,^ [@B34] We found no association between obesity and late-onset asthma in our sample. This is an important observation because it indicates that age at symptom onset did not bias the relationship between obesity and asthma severity in our study.

Data in the literature show that, in terms of pulmonary function, obese individuals have restrictive lung disease, probably because of changes in body structure.[@B35] ^,^ [@B36] Although we did not measure lung volumes to confirm the presence of restrictive lung disease, decreased FVC values in obese individuals indicate a higher frequency of restrictive lung disease than that found in nonobese individuals. We also observed that, when obesity was defined on the basis of AC, lung volumes were lower. The literature reports that increased abdominal adiposity may reflect poorer pulmonary function.[@B31] The pathophysiological mechanism of more severe asthma in obese individuals might be in part related to structural changes in the rib cage rather than exclusively to a lower airway pathology. This hypothesis is supported by the lack of association between obesity and obstructive lung disease in our sample.

Obese individuals with asthma had a higher frequency of comorbidities. Obesity is associated with an increased frequency of comorbidities in individuals without asthma; therefore, our findings were expected.[@B37] ^,^ [@B38] Comorbidities might contribute to a change in asthma severity in obese individuals, which may be clarified in future studies.

One strength of the present study is that we evaluated subjects recruited from the community and from primary and secondary care clinics, which increases the external validity of the findings. Another strength is that the diagnosis of asthma was validated by a specialist. In the case of severe asthma, it is important to make the differential diagnosis with COPD and other respiratory diseases, and that diagnosis was validated by two specialists to avoid the inclusion of patients without asthma. However, as in all cross-sectional studies, it was not possible to explore the causal relationship between obesity and the study variables. A question arises as to whether neutrophilic inflammation is a different phenotype of obese individuals with asthma or is also a characteristic of obese individuals without asthma. This question still represents a gap in current knowledge and may be answered by analyzing data on individuals without asthma.

In conclusion, we found that obese subjects with asthma have poorer asthma control and poorer quality of life, require higher doses of inhaled corticosteroid, and experience a reduction in some pulmonary function parameters, such as FVC. In addition, we found a smaller proportion of subjects with eosinophilic asthma and a lower frequency of atopy among obese individuals with asthma. Therefore, our study can satisfactorily validate data on a common combination in a Brazilian population and may help improve knowledge about the influence of obesity on asthma. However, the clinical relevance of these observations should be interpreted with caution and should be examined in future studies with analyses specific to that end.

Study carried out at the Núcleo de Excelência em Asma/Programa para o Controle da Asma na Bahia - ProAR - Salvador (BA) Brasil.
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[^1]: BMI: body mass index; and GERD: gastroesophageal reflux disease. ^a^Values expressed as n (%), as mean ± SD, or as median (interquartile range). ^b^Low level of education: being illiterate or having had fewer than 5 years of schooling. ^c^Comorbidities: hypertension, diabetes, and/or dyslipidemia. ^d^Severe depression: severe level of depression as assessed by the Beck Depression Inventory. ^e^High dose of medication: based on use of inhaled corticosteroids. \*Chi-square test for categorical variables and Kruskal-Wallis test for continuous variables.

[^2]: BMI: body mass index; BD: bronchodilator; ACQ-6: 6-item Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; and GERD: gastroesophageal reflux disease. ^a^Values expressed as n (%) or as median (interquartile range). ^b^FEV~1~ \< 80% and FEV~1~/FVC \< the lower limit of normal.[@B23] ^)^ \*Kruskal-Wallis test for continuous variables and chi-square test for categorical variables.

[^3]: GERD: gastroesophageal reflux disease. ^a^Values expressed as n (%), as mean ± SD, or as median (interquartile range). ^b^Low level of education: being illiterate or having had fewer than 5 years of schooling. ^c^Comorbidities: hypertension, diabetes, and/or dyslipidemia. ^d^Severe depression: severe level of depression as assessed by the Beck Depression Inventory. ^e^High dose of medication: based on use of inhaled corticosteroids. \*Chi-square test for categorical variables and Kruskal-Wallis test for continuous variables.

[^4]: BD: bronchodilator; ACQ-6: 6-item Asthma Control Questionnaire; and AQLQ: Asthma Quality of Life Questionnaire. ^a^Values expressed as n (%) or as median (interquartile range). ^b^FEV~1~ \< 80% and FEV~1~/FVC \< lower limit of normal.[@B23] ^)^ \*Kruskal-Wallis for continuous variables and chi-square test for categorical variables
